b8b20101_mor_lysis_syndrome_and_in_gout__sburicase__an_uricolytic_agent
Its formulation is oral since 1966. Since 1999 a new intravenous formulation (not yet available in Italy) was introduced in USA
An intravenous formulation is available
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
Rasburicase: an uricolytic agent